REASON TO SMILE: Gleevec's pioneer Brian Druker at a May press conference
announcing the cancer drug's approval.
Image: PATRICIA CORDELL The Oregonian/Corbis/Sygma
Approved for use this past May, Gleevec was celebrated as the first in a wave
of supremely effective cancer drugs that home in on tumors without harming healthy cells. In clinical trials, 90 percent of patients in early
This article was originally published with the title Cancer in the Crosshairs.
Subscribe
Buy This Issue
Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.
Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.
See what we're tweeting about
Comments
Add Comment